Cargando…

Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma

BACKGROUND: Gallbladder cancer (GBC) has a poor prognosis. Although complete surgical resection is the only successful approach for improving survival, additional therapeutic modalities are required for recurrent or surgically unresectable GBCs. MATERIALS AND METHODS: To determine the expression sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sung, You-Na, Kim, Sung Joo, Jun, Sun-Young, Yoo, Changhoon, Kim, Kyu-Pyo, Lee, Jae Hoon, Hwang, Dae Wook, Hwang, Shin, Lee, Sang Soo, Hong, Seung-Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339709/ https://www.ncbi.nlm.nih.gov/pubmed/34367955 http://dx.doi.org/10.3389/fonc.2021.658564

Ejemplares similares

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen
por: Yoo, Changhoon, et al.
Publicado: (2017)

Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration Detection
por: Lim, Dong-Hoon, et al.
Publicado: (2023)

Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location
por: Sung, Min Kyu, et al.
Publicado: (2021)

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
por: Yoo, Changhoon, et al.
Publicado: (2021)

Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis
por: Yoo, Changhoon, et al.
Publicado: (2020)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Prognostic factors associated with early mortality after surgical resection for pancreatic adenocarcinoma
por: Kwak, Bong Jun, et al.
Publicado: (2014)

Benefit of Adjuvant Chemoradiotherapy in Resected Gallbladder Carcinoma
por: Kim, Tae Hyun, et al.
Publicado: (2019)

Low frequency of mismatch repair deficiency in gallbladder cancer
por: Goeppert, Benjamin, et al.
Publicado: (2019)

Clinicopathologic Features of Polypoid Lesions of the Gallbladder and Risk Factors of Gallbladder Cancer
por: Kwon, Wooil, et al.
Publicado: (2009)

Extent of resection for T2N0 gallbladder carcinoma regarding concurrent extrahepatic bile duct resection
por: Gwark, Sung-Chan, et al.
Publicado: (2012)

Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients
por: Kim, Mi-Ju, et al.
Publicado: (2017)

Validation of the 8th Edition of the American Joint Committee on Cancer Staging System for Gallbladder Cancer and Implications for the Follow-up of Patients without Node Dissection
por: Sung, You-Na, et al.
Publicado: (2020)

Mixed lymphoepithelioma-like carcinoma and adenocarcinoma of the gallbladder
por: Choi, Nam Kyu, et al.
Publicado: (2016)

Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
por: Lee, Woohyung, et al.
Publicado: (2020)

Survival analysis following resection of AJCC stage III gallbladder carcinoma based on different combinations of T and N stages
por: Hwang, Kyoung-Yeon, et al.
Publicado: (2015)

Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only
por: Shin, Su-Jin, et al.
Publicado: (2018)

A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer
por: An, Ji Yeong, et al.
Publicado: (2020)

Validation of Prediction Models for Mismatch Repair Gene Mutations in Koreans
por: Lee, Soo Young, et al.
Publicado: (2016)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
por: Yoo, Changhoon, et al.
Publicado: (2019)

Clinical necessity of the immunohistochemical reassessment of para-aortic lymph nodes in resected pancreatic ductal adenocarcinoma
por: CHOI, SUNG HOON, et al.
Publicado: (2013)

The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study
por: Shin, Sang Hyun, et al.
Publicado: (2017)

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
por: Lee, Seung Jae, et al.
Publicado: (2022)

Role of common bile duct resection in T2 and T3 gallbladder cancer patients
por: Lim, Jin Hong, et al.
Publicado: (2018)

Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma
por: Heby, Margareta, et al.
Publicado: (2018)

Arterial resection during pancreatectomy for pancreatic ductal adenocarcinoma with arterial invasion: A single-center experience with 109 patients
por: Kwon, Jaewoo, et al.
Publicado: (2020)

FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment
por: Chae, Heejung, et al.
Publicado: (2018)

Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
por: Jeong, Hyehyun, et al.
Publicado: (2021)

Preoperative serum carbohydrate antigen 19-9 levels predict early recurrence after the resection of early-stage pancreatic ductal adenocarcinoma
por: Hong, Sarang, et al.
Publicado: (2021)

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
por: Lee, Kyoungmin, et al.
Publicado: (2020)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry
por: Jung, Jiyoon, et al.
Publicado: (2017)

Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis
por: Go, Se-Il, et al.
Publicado: (2016)

Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer
por: Punturi, Nindo B., et al.
Publicado: (2021)

Hepatoid adenocarcinoma of the gallbladder with production of alpha-fetoprotein
por: Lee, Jae Hoon, et al.
Publicado: (2011)

EUS-guided fine-needle biopsy of gallbladder polypoid lesions
por: Kang, Sung Hoon, et al.
Publicado: (2020)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Novel Preoperative Nomogram for Prediction of Futile Resection in Patients Undergoing Exploration for Potentially Resectable Intrahepatic Cholangiocarcinoma
por: Nam, Kwangwoo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k7hc20t72btchj76nouj4m71nf